Skip Navigation



Annals of Oncology Advance Access published online on May 12, 2005
Annals of Oncology, doi:10.1093/annonc/mdi196
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/6/845    most recent
mdi196v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Punt, C. J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Punt, C. J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Editorial

Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?

C. J. A. Punt 1*

1 Department of Medical Oncology, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands

* To whom correspondence should be addressed.
C. J. A. Punt, E-mail: c.punt{at}onco.umcn.nl



This article has no Abstract.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
D. Arnold, T. Hohler, C. Dittrich, F. Lordick, T. Seufferlein, J. Riemann, E. Woll, T. Herrmann, A. Zubel, and H.-J. Schmoll
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group
Ann. Onc., August 1, 2008; 19(8): 1442 - 1449.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tabernero, E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, T. Andre, J.-L. Van Laethem, P. Soulie, E. Casado, C. Verslype, et al.
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5225 - 5232.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M Koopman, N. Antonini, J Douma, J Wals, A. Honkoop, F. Erdkamp, R. de Jong, C. Rodenburg, G Vreugdenhil, J. Akkermans-Vogelaar, et al.
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
Ann. Onc., October 1, 2006; 17(10): 1523 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger, D. P. Ryan, J. W. Clark, M. H. Kulke, C. C. Earle, M. Vincitore, A. Michelini, S. Sheehan, et al.
Phase II Study of Capecitabine, Oxaliplatin, and Erlotinib in Previously Treated Patients With Metastastic Colorectal Cancer
J. Clin. Oncol., April 20, 2006; 24(12): 1892 - 1897.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.